Akebia extends manufacturing supply agreement with Siegfried through 2026

Akebia Therapeutics, Inc.

Exercised option to extend Master Manufacturing Services and Supply Agreement with Siegfried Evionnaz SA.
Term extended from December 31, 2024 to December 31, 2026.
Extension notice provided on December 14, 2023; all other terms unchanged.
Supply continuity secured for active pharmaceutical ingredient manufacturing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Akebia Therapeutics, Inc. amended Amendment No. 5 Master Manufacturing Services and Supply Agreement with Siegfried Evionnaz SA (effective 2023-02-28).

Action: amendment
Agreement: supply
Counterparty: Siegfried Evionnaz SA
Effective: 2023-02-28

Exact text from the filing

As previously disclosed, on February 28, 2023, Keryx Biopharmaceuticals, Inc., a wholly-owned subsidiary of Akebia Therapeutics, Inc. (the “Company”), and Siegfried Evionnaz SA (“Siegfried”) entered into Amendment No. 5 Master Manufacturing Services and Supply Agreement (the “Amendment”), which further amended the Master Manufacturing Services and Supply Agreement dated December 20, 2017 (as amended, the “Supply Agreement”).

View on SEC.gov

Browse all material agreements →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001517022-23-000046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.